Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations

Most tumors with activating MAPK (mitogen-activated protein kinase) pathway alterations respond poorly to MEK inhibitors alone. Here, we evaluated combination therapy with MEK inhibitor selumetinib and MDM2 inhibitor KRT-232 in TP53 wild-type and MAPK altered colon and thyroid cancer models. In vitr...

Descripción completa

Detalles Bibliográficos
Autores principales: Pairawan, Seyed, Akcakanat, Argun, Kopetz, Scott, Tapia, Coya, Zheng, Xiaofeng, Chen, Huiqin, Ha, Min Jin, Rizvi, Yasmeen, Holla, Vijaykumar, Wang, Jing, Evans, Kurt W., Zhao, Ming, Busaidy, Naifa, Fang, Bingliang, Roth, Jack A., Dumbrava, Ecaterina Ileana, Meric-Bernstam, Funda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786858/
https://www.ncbi.nlm.nih.gov/pubmed/35075200
http://dx.doi.org/10.1038/s41598-022-05193-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786858/
https://www.ncbi.nlm.nih.gov/pubmed/35075200
http://dx.doi.org/10.1038/s41598-022-05193-z

Ejemplares similares